Breaking News

Financial Report: InterMune

May 2, 2014

Esbriet revenues climb 188%


1Q Revenues: $30.3 million (+188%)

1Q Loss: $53.6 million (loss of $49.9 million in 1Q13)

Comments: Esbriet revenue in the quarter was $30.3 million, up 188%. R&D expenses were $32.1 million, up 24%, attributed to activities to complete the ASCEND Phase III trial, a higher number of patients in the RECAP extension study of pirfenidone, and activities related to the pirfenidone NDA resubmission.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks